New drug therapies and their effect on the skin;Neue Therapeutika und ihre Auswirkungen auf die Haut

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 7, 2009, Pages 623-636

  Treudler, Regina ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Adverse drug reaction; Biological response modifiers; Cancer skin effects; EGFR inhibitors; Management; TNF antagonist

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ALPHA INTERFERON; ANTIDIABETIC AGENT; BASILIXIMAB; BETA INTERFERON; BEVACIZUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; CYCLOSPORIN; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; INTERLEUKIN 2; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; PARACETAMOL; RETINOID; RITUXIMAB; STEROID; TRASTUZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADRENAL CORTEX INSUFFICIENCY; ALOPECIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ASTHMA; ATOPIC DERMATITIS; BLISTER; BLOOD PRESSURE; BULLOUS PEMPHIGOID; CAPILLARY LEAK SYNDROME; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; COLON CANCER; CROHN DISEASE; CROSS REACTION; CUSHING SYNDROME; DEPRESSION; DERMATOMYOSITIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DYSPNEA; EPITHELIUM TUMOR; FLU LIKE SYNDROME; FLUSHING; GENERALIZED EDEMA; GRAFT REJECTION; HAIR DISEASE; HEAD AND NECK CANCER; HEADACHE; HEART FAILURE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INFECTION; INJECTION SITE URTICARIA; ISCHEMIA; ISCHEMIC HEART DISEASE; JOINT STIFFNESS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY GRAFT REJECTION; LICHEN PLANUS; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; MYALGIA; NAIL DISEASE; NAUSEA; NONHODGKIN LYMPHOMA; PAIN; PARONYCHIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PEMPHIGUS VULGARIS; POLYARTERITIS NODOSA; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RAYNAUD PHENOMENON; REVIEW; RHAGADE; RHEUMATOID ARTHRITIS; RISK FACTOR; SARCOIDOSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DEFECT; SKIN DISEASE; SKIN EXFOLIATION; STRIDOR; SWEATING; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENESIS; THORAX PAIN; ULCERATIVE COLITIS; URTICARIA; VASCULITIS; VIRUS INFECTION; VITILIGO; XEROSIS;

DERMATOLOGY; DRUG ERUPTIONS; GERMANY; HUMANS; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68149129575     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07139.x     Document Type: Review

References (13)

1. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006 61 (8 912 20. Review.
2. Trefzer U, Hofmann M, Sterry W. Kutane Nebenwirkungen klinisch relevanter Zytokintherapien. Dtsch Med Wochenschr 2003 128 : 1782 7.
3. Myer L, Young Y. Infusion reactions and their management. Gastroenterol Clin North Am 2006 35 (4 857 66.
4. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008 358 (11 1109 17.
5. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008 13 (6 725 32. Review.
6. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007 120 (6 1378 81.
7. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007 156 (3 486 91.
8. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008 9 (1 1 14.
9. Davaine AC, Saraux A, Prigent S, Kupfer-Bessaguet I, Roswag D, Plantin P, Schoenlaub P, Talarmin F, Zagnoli A, Misery L. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. J Eur Acad Dermatol Venereol 2008 22 (12 1471 7.
10. Ramos-Casals M, Brito-Zerón P, Mũoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007 86 (4 242 51.
11. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res 2009 301 (1 99 105.
12. Lynch TJ Jr., Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007 12 (5 610 21.
13. Segaert S, Tabernero J, Chosidow O, Dirschka T, Eisner J, Mancini L, Maughan T, Morere JF, Santoro A, Sobrero A, van Cutsem E, Layton A. Behandlung der Hautreaktionen bei EGFR-spezifischer Tumortherapie (Epidermaler Wachstumsfaktor Rezeptor). J Deutsch Dermatol Ges 2005 3 : 599 606.